Why AstraZeneca plc Should Be A Candidate For Your 2014 ISA

AstraZeneca plc (LON: AZN) is heading back to growth.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

astrazenecaThe UK’s pharmaceuticals giants have been facing the ‘patent cliff’ problem for a few years now, with protection of some of their blockbuster drugs expiring and competition from generic alternatives growing.

And in the recent past AstraZenenca (LSE: AZN) (NYSE: AZN.US) has lagged behind rival GlaxoSmithKline in the race to find alternatives — Glaxo has been significantly more successful on the acquisition trail and in biotechnology expansion.

On the turn

But over the past year or two things have been changing, and I’m going to tell you why I think AstraZeneca is worth considering for some of your new 2014 ISA allowance of £11,760 (or for any still unused this year).

The effects of the patent-cliff slowdown are painfully clear, with adjusted earnings per share (EPS) now having fallen for three years in a row — culminating with a 58% fall for the year ended December 2013!

In those results, we heard that revenue had declined 6%, with a couple of blockbusters dropping out of patent protection, including the big-selling antipsychotic drug Seroquel — and Crestor, the cholesterol-lowering statin, is due to lose protection soon.

Dividends stretched

The dividend us holding up and was maintained at 280 cents per share for 2013, with the board saying it is “committed to the company’s progressive dividend policy“. But the cover is declining and payments at current levels are not going to be sustainable for much longer. So the big question is whether earnings growth will resume before any cut to the dividend is needed.

Even though 2013 results were disappointing, I think the answer is yes.

Return to strength

When Pascal Soriot took on the chief executive role in October 2012, he quickly established a road map back to growth — AstraZenenca was to divest itself of low-margin interests, focus on its key strengths, get research and development kick-started again, and get that drugs pipeline back up to strength.

And the latest results did bring us some upbeat news on those fronts.

The company’s pipeline now includes 11 candidates that have reached Phase III or registration, which nearly is twice the number at the same stage a year previously, and there are currently 19 potential candidates for Phase III starts in 2014-15.

AstraZeneca is also rapidly integrating the diabetes assets acquired from Bristol-Myers Squibb after taking full control of the two firms’ previous alliance.

What’s the outlook?

In the short term, things still look tough, with core EPS “expected to decline in the teens” in 2014. But Mr Soriot did say that he is “confident that we can return to growth faster than anticipated“.

Are the markets convinced?

With the share price up more than 30% over the past 12 months to 4,055p, even after a small dip in response to those 2013 figures, I think the answer is a clear yes. And what’s encouraging is that, with revenue still expected to be at 2013 levels by 2017, it’s with a longer-term horizon rather than the short-termism typically shown by the City.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Alan does not own any shares in AstraZeneca or GlaxoSmithKline. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Happy young female stock-picker in a cafe
Investing Articles

No savings at 25? I’d start by investing £3k in these 3 red-hot FTSE 100 shares

Harvey Jones thinks these three FTSE 100 stocks would be a great way to kickstart a portfolio of UK shares.…

Read more »

Young Black woman using a debit card at an ATM to withdraw money
Investing Articles

Up 35% from this year’s low! Here’s where I think Lloyds shares are headed in H2 of 2024

My Lloyds shares are already doing well this year but that’s not guaranteed to continue. What factors could turn the…

Read more »

Investing Articles

Approaching £5, is there still growth ahead for the Rolls-Royce share price?

The Rolls-Royce share price has been flying in the last year. But is there more growth ahead or should investors…

Read more »

Happy young plus size woman sitting at kitchen table and watching tv series on tablet computer
Investing Articles

Could Raspberry Pi be a growth share to buy and hold?

Our writer explains why he thinks a newly-listed UK growth share could have a bright future -- and considers whether…

Read more »

A pastel colored growing graph with rising rocket.
Market Movers

The FTSE 100 jumps after the Bank of England meeting. Here’s what’s next

Jon Smith runs over the takeaways from the Bank of England meeting today and flags up which FTSE 100 stocks…

Read more »

Middle-aged white male courier delivering boxes to young black lady
Investing Articles

How I’d start investing in great value UK shares with £10,000 today

Harvey Jones can see a heap of UK shares he'd like to add to an ISA today. Many combine low…

Read more »

Young Black woman looking concerned while in front of her laptop
Investing Articles

Why did the YouGov share price just crash 37%?

The YouGov share price has been weak for a while. But that's nothing compared to what happened after this profit…

Read more »

Middle-aged white man pulling an aggrieved face while looking at a screen
Investing Articles

YouGov shares collapse 37%! What’s going on with this AIM stock?

Our writer takes a look at why YouGov shares fell dramatically today and assesses whether this might be a chance…

Read more »